# RASA1

Source: https://onco.cc/targets/rasa1/  
OnCo record `rasa1` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

RASA1 (Ras GTPase-activating protein 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma, Colorectal cancer, Lung cancer and 4 more.

## Summary

GTPase-activating protein (GAP) that stimulates the intrinsic GTPase activity of Ras proteins, such as NRAS, facilitating their transition from the active GTP-bound state to the inactive GDP-bound state, thereby terminating Ras signalling.

CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Trametinib. Open Targets scores its association with cancer at 0.77 (direct and indirect evidence; datatypes literature 0.94, animal model 0.42, genetic association 0.28, somatic mutation 0.91). IntOGen calls it a driver in 2 cohorts (0 activating, 2 loss-of-function), covering Head and Neck Squamous Cell Carcinoma, Lung Squamous Cell Carcinoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: RAS p21 protein activator 1; Ras GTPase-activating protein 1; CM-AVM; p120GAP; p120RASGAP; p120
- Tags: cancer-genes-wave
- Symbol: RASA1
- Class: tumor-suppressor
- Biology: GTPase-activating protein (GAP) that stimulates the intrinsic GTPase activity of Ras proteins, such as NRAS, facilitating their transition from the active GTP-bound state to the inactive GDP-bound state, thereby terminating Ras signalling. Location: Cytoplasm (UniProt). Locus 5q14.3 (HGNC).
- Where found: Head and neck squamous cell carcinoma: IntOGen driver in 1 cohort (HNSC); Colorectal cancer: Open Targets association 0.53 with colorectal cancer (MONDO_0005575); Lung cancer: Open Targets association 0.53 with lung cancer (MONDO_0008903); Skin cancer: Open Targets association 0.52 with skin cancer (MONDO_0002898); Gastric & gastro-oesophageal junction cancer: Open Targets association 0.51 with gastric cancer (MONDO_0001056); Non-small-cell lung cancer: CIViC evidence names this disease; IntOGen driver in 1 cohort (LUSC)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:9871: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9871
- UniProt P20936: https://www.uniprot.org/uniprotkb/P20936/entry
- NCBI Gene 5921: https://www.ncbi.nlm.nih.gov/gene/5921
- Ensembl ENSG00000145715: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000145715

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Basal cell carcinoma](https://onco.cc/cancers/basal-cell-carcinoma/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)

---
JSON: https://onco.cc/api/v1/entities/rasa1.json